| Name | MC1742 |
| Description | MC1742 is a broad-spectrum HDAC inhibitor, inhibiting HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, and HDAC11. MC1742 inhibits the growth of parasites in vitro, blocking the growth of Toxoplasma gondii tachyzoites and severely disrupting the expression of parasitic genes. MC1742 has potential anticancer activity, inhibiting the growth arrest, apoptosis, and growth of cancer cells. MC1742 has potential anticancer activity, inhibiting growth arrest, apoptosis and differentiation of cancer cells. |
| In vitro | MC1742 is a potent HDAC inhibitor with IC50 values of 0.1 μM, 0.11 μM, 0.02 μM, 0.007 μM, 0.61 μM, 0.04 μM, and 0.1 μM for HDAC1, HDAC2, HDAC3, HDAC6, HDAC8, HDAC10, and HDAC11, respectively.MC1742 was able to increase the levels of acetylated-H3 and acetylated microtubule proteins and inhibit the proliferation of cancer stem cells.
MC1742 (0.5 and 2 μM; 24 h) was able to enhance acetylation levels in a dose-dependent manner, as evidenced by patchy nuclear staining of acetylated histone H3.
MC1742 (0.5, 1 and 2 μM; 24, 48 and 72 h) significantly induced apoptosis in all cancer stem cell cultures.
MC1742 (0.025-0.5 μM; 14 days) was able to significantly promote bone vesicle formation with a dose-dependent effect. [1] |
| Storage | store at low temperature,keep away from direct sunlight | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 160 mg/mL (404.57 mM), Sonication is recommended.
|
| Keywords | MC-1742 | MC1742 | HDAC | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Manganese chloride (tetrahydrate) | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
United States
